Tercica, Inc.
Brisbane, CA 94005 (Map) Phone: 650-624-4900
Fax: 650-624-4940
http://www.tercica.com
Overview
Hey, cut Tercica some slack -- it's feeling a bit hormonal. The company's drug therapies focus on the treatment of growth disorders. The company's lead product Increlex (rhIGF-1) treats children with severe primary insulin-like growth factor deficiency, and its Somatuline Depot (lanreotide) is for the treatment of acromegaly (excess growth hormones) in adults. Cambrex Biosciences manufactures Increlex for the company. Tercica licenses manufacturing and other technology and intellectual property related to the recombinant growth hormone rhIGF-1 from Genentech. Tercica is a subsidiary of European drugmaker Ipsen.
Sample OverviewKey Numbers from Hoover's UK
Key financials for Tercica, Inc.
| Company Type | Subsidiary of Ipsen |
|---|---|
| Fiscal Year-End | December |
Key People from Hoover's UK
Key people and executives for Tercica, Inc.
| Chairman | Alexander E. (Alex) Barkas (Subscribers see complete biographies -- view sample)
|
|---|---|
| President and COO | Richard A. King |
| VP Human Resources and Information Technology | William Yates |
Top Competitors from Hoover's UK
Top competitors of Tercica, Inc.
There are 13 competitors for Tercica; see more.
